PDS Biotechnology Corporation – NASDAQ:PDSB

Add to watchlist

$1.16

-0.55

-32.16%

Market closed

Open in 3 days

-58.19%

month

-58.19%

quarter

-66.34%

year

Market Cap	61.72M
Enterprise value	N/A

P/E	-4.05
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	4.05
PEG ratio	0.03
EPS	-1.35

Revenue	N/A
EBITDA	-42.93M
Income	-43.88M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

PDS Biotechnology Corporation (NASDAQ:PDSB): Profit margin
Jun 2023	0	-11.53M
Sep 2023	0	-10.84M
Dec 2023	0	-10.89M
Mar 2024	0	-10.60M

PDS Biotechnology Financials Estimate

Q Y

PDS Biotechnology Corporation (NASDAQ:PDSB): Analyst Estimates
Dec 2023	0	-10.89M
Mar 2024	0	-10.60M
Sep 2025	0	-11.14M
Dec 2025	0	-11.14M

Analysts Price target
Financials & Ratios estimates

PDS Biotechnology Corporation (NASDAQ:PDSB): Debt to assets
Jun 2023	63754250	31.31M	49.11%
Sep 2023	57187821	32.70M	57.19%
Dec 2023	59390080	33.25M	56%
Mar 2024	69006366	31.82M	46.12%

PDS Biotechnology Corporation (NASDAQ:PDSB): Cash Flow
Jun 2023	-4.81M	240.00K
Sep 2023	-7.17M	802.32K
Dec 2023	-8.45M	10.76M
Mar 2024	-9.93M	20.01M

PDS Biotechnology alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

PDS Biotechnology Corporation (NASDAQ:PDSB): Employee count
Aug 2023	26
Sep 2023	26
Oct 2023	26
Nov 2023	26
Dec 2023	26
Jan 2024	26
Feb 2024	26
Mar 2024	26
Apr 2024	26
May 2024	25
Jun 2024	25
Jul 2024	25

PDS Biotechnology
Hedge Funds Holdings Q1 2023

8.04% -15.89%

of PDSB is owned by hedge funds

39 -24

hedge funds hold PDSB stock

2.30M -4.51M

shares is hold by hedge funds

PDSB hedge funds holdings changes

PDS Biotechnology
Insider Trading

PDS Biotechnology Corporation (NASDAQ:PDSB): Insider trades (number of shares)
Period	Buy	Sel
Jun 2021	51175	0
Dec 2021	3100	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	2 Dec 2022	BEDU-ADDO FRANK director, officer..	Stock Option (Right to Buy)	219,535	$6.57	$1,442,345
Option	2 Dec 2022	BEDU-ADDO FRANK director, officer..	Common Stock	219,535	$6.57	$1,442,345
Purchase	13 Dec 2021	HILL MATTHEW C officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	2,500	$9	$22,500
Purchase	13 Dec 2021	HILL MATTHEW C officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	100	$9	$900
Purchase	13 Dec 2021	HILL MATTHEW C officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	100	$9	$900
Purchase	13 Dec 2021	HILL MATTHEW C officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	400	$8.9	$3,560
Option	16 Jun 2021	BLOOMQUIST DELYLE W director director	Common Stock	2,970	$5.99	$17,790
Purchase	16 Jun 2021	BLOOMQUIST DELYLE W director director	Common Stock	10,000	$9.88	$98,780
Option	16 Jun 2021	BLOOMQUIST DELYLE W director director	Stock Option (Right to Buy)	2,970	$5.99	$17,790
Purchase	15 Jun 2021	FREITAG GREGORY GENE director director	Common Stock	5,882	$8.5	$49,997

PDSB insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS AND COMPOSITIONS COMPRISING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION Filling date: 22 Nov 2021 Issue date: 26 May 2022	22 Nov 2021	26 May 2022
Application	Application STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS Filling date: 22 Jul 2021 Issue date: 3 Feb 2022	22 Jul 2021	3 Feb 2022
Application	Application VACCINE COMPOSITIONS AND METHODS OF USE Filling date: 22 Jul 2021 Issue date: 25 Nov 2021	22 Jul 2021	25 Nov 2021
Application	Application CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE Filling date: 22 Jul 2021 Issue date: 11 Nov 2021	22 Jul 2021	11 Nov 2021
Application	Application STIMULATION OF AN IMMUNE RESPONSE BY CATIONIC LIPIDS Filling date: 22 Jul 2021 Issue date: 11 Nov 2021	22 Jul 2021	11 Nov 2021
Application	Application STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS Filling date: 25 Mar 2021 Issue date: 7 Oct 2021	25 Mar 2021	7 Oct 2021
Application	Application CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE Filling date: 1 Oct 2020 Issue date: 8 Apr 2021	1 Oct 2020	8 Apr 2021
Grant	Grant Utility: Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions Filling date: 28 Mar 2019 Issue date: 10 Nov 2020	28 Mar 2019	10 Nov 2020
Application	Application STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS Filling date: 12 Jun 2020 Issue date: 22 Oct 2020	12 Jun 2020	22 Oct 2020
Grant	Grant Utility: Stimulation of an immune response by enantiomers of cationic lipids Filling date: 12 Sep 2017 Issue date: 7 Jul 2020	12 Sep 2017	7 Jul 2020

PDS Biotechnology
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 27 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 14 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 15 May 2023	Q1 2023 Earnings Call Transcript

PDSB earnings call transcripts

PDS Biotechnology
Executives

Insider	Age	Compensation
Dr. Frank K. Bedu-Addo Ph.D. (1964) Pres, Chief Executive Officer & Director	61	$675,000
Ms. Lauren V. Wood M.D. (1960) Chief Medical Officer	65	$416,380
Dr. Gregory L. Conn (1955) Chief Scientific Officer	70	$384,790

PDS Biotechnology
Latest News

Friday, 6 December 2024
08:00	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 3 December 2024
08:00	PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET	globenewswire.com
Wednesday, 20 November 2024
10:35	Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround	zacks.com
Thursday, 14 November 2024
11:18	PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript	seekingalpha.com
11:03	EMV Capital highlights progress update from portfolio company PDS Biotech	proactiveinvestors.co.uk
Wednesday, 6 November 2024
08:00	PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time	globenewswire.com
Tuesday, 22 October 2024
13:06	PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know	zacks.com
Tuesday, 15 October 2024
11:00	Best Momentum Stocks to Buy for October 15th	zacks.com
Wednesday, 2 October 2024
08:00	PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation	globenewswire.com
Monday, 23 September 2024
10:39	PDS Biotechnology: Continuing The Holding Pattern	seekingalpha.com
Monday, 9 September 2024
08:00	PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024	globenewswire.com
Tuesday, 3 September 2024
08:00	PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Wednesday, 7 August 2024
08:00	PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024	globenewswire.com
Friday, 2 August 2024
09:12	PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)	seekingalpha.com
Thursday, 1 August 2024
07:45	PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer	globenewswire.com
Wednesday, 31 July 2024
16:01	PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time	globenewswire.com
Wednesday, 15 May 2024
08:00	PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results	globenewswire.com
Thursday, 9 May 2024
17:46	PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer	globenewswire.com
Tuesday, 7 May 2024
08:00	PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024	globenewswire.com
Friday, 3 May 2024
08:00	PDS Biotechnology Announces Details of Virtual KOL Event	globenewswire.com
Thursday, 2 May 2024
08:00	PDS Biotech Appoints Stephan Toutain as Chief Operating Officer	globenewswire.com
Tuesday, 23 April 2024
08:00	PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer	globenewswire.com
Wednesday, 27 March 2024
12:17	PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 20 March 2024
08:00	PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results	GlobeNewsWire
Tuesday, 2 January 2024
13:32	All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy	Zacks Investment Research
Tuesday, 14 November 2023
12:17	PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 7 November 2023
08:00	PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results	GlobeNewsWire
Tuesday, 26 September 2023
08:00	PDS Biotech to Present at the LD Micro Main Event XVI	GlobeNewsWire
Wednesday, 20 September 2023
16:05	PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference	GlobeNewsWire
Wednesday, 6 September 2023
16:05	PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 22 Apr 2024

Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts
Seeking Alpha 26 Jan 2024

PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data
Seeking Alpha 14 Aug 2023

PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
Seeking Alpha 13 Aug 2023

The Prognosis For PDS Biotechnology
Seeking Alpha 27 May 2023

PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment Prospects
Seeking Alpha 26 Apr 2023

PDS Biotechnology: Late-Stage Biotech With Enormous Potential
Seeking Alpha 5 Apr 2023

PDS Biotechnology's PDS0101 Shows Potential In HPV-Positive Head And Neck Cancers
Seeking Alpha 24 Oct 2022

PDS Biotech: Strong Data Indicate Further Upside
Seeking Alpha 27 May 2022

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Seeking Alpha 22 Feb 2022

PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

Frequently Asked Questions (FAQ)

What's the price of PDS Biotechnology stock today?

One share of PDS Biotechnology stock can currently be purchased for approximately $1.16.
When is PDS Biotechnology's next earnings date?

Unfortunately, PDS Biotechnology's (PDSB) next earnings date is currently unknown.
Does PDS Biotechnology pay dividends?

No, PDS Biotechnology does not pay dividends.
How much money does PDS Biotechnology make?

PDS Biotechnology has a market capitalization of 61.72M.
What is PDS Biotechnology's stock symbol?

PDS Biotechnology Corporation is traded on the NASDAQ under the ticker symbol "PDSB".
What is PDS Biotechnology's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of PDS Biotechnology?

Shares of PDS Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are PDS Biotechnology's key executives?
PDS Biotechnology's management team includes the following people:
- Dr. Frank K. Bedu-Addo Ph.D. Pres, Chief Executive Officer & Director(age: 61, pay: $675,000)
- Ms. Lauren V. Wood M.D. Chief Medical Officer(age: 65, pay: $416,380)
- Dr. Gregory L. Conn Chief Scientific Officer(age: 70, pay: $384,790)
How many employees does PDS Biotechnology have?

As Jul 2024, PDS Biotechnology employs 25 workers, which is 4% less then previous quarter.
When PDS Biotechnology went public?

PDS Biotechnology Corporation is publicly traded company for more then 9 years since IPO on 30 Sep 2015.
What is PDS Biotechnology's official website?

The official website for PDS Biotechnology is pdsbiotech.com.
Where are PDS Biotechnology's headquarters?

PDS Biotechnology is headquartered at 25B Vreeland Road, Florham Park, NJ.
How can i contact PDS Biotechnology?

PDS Biotechnology's mailing address is 25B Vreeland Road, Florham Park, NJ and company can be reached via phone at +800 2083343.

PDS Biotechnology Corporation

pdsbiotech.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

+800 2083343

25B Vreeland Road
Florham Park, NJ 07932

CIK: 0001472091
ISIN: US70465T1079
CUSIP: 70465T107